British Journal of Haematology · 2021 · 35 citations · 24 references
Life SciencesNeurologyOncologyImmunopathologyNeurodegenerationNeuroimmunologyAutoimmune DiseasesGenetic DisordersHereditary Cancer SyndromesMalignant NeoplasmsNeurogenetic DisordersRegulatory T Cell DysfunctionAtaxia SyndromesHereditary AtaxiasMuscle Weakness ProgressionNaive T-cell ActivationNeonatal ScreeningPediatric AtaxiaPediatric Muscle WeaknessT Cell-mediated Pathology
Ataxia‑telangiectasia is a hereditary immune‑system disorder characterized by neurodegeneration, early‑onset cerebellar ataxia, oculomotor apraxia, telangiectasia, and muscle weakness, and can be identified by neonatal screening for severe T‑cell deficiency. The study emphasizes the necessity of cancer surveillance, prevention, and optimal treatment for patients with A‑T. The authors retrospectively reviewed 69 A‑T patients from 2002 to 2019. Among the 69 patients, 25% developed cancer, with a median overall survival of 26.9 years; those with malignancies had a median OS of 2.11 years and a 15‑fold higher risk of death from hematologic cancers, and males had a higher cancer risk than females.
Ataxia-telangiectasia (A-T) is a hereditary immune system disorder with neurodegeneration. Its first neurologic symptoms include ataxic gait in early childhood, with slowly progressive cerebellar ataxia, oculomotor apraxia, oculocutaneous telangiectasia, and progressive muscle weakness. Neonatal screening for severe T-cell deficiency was recently found to diagnose A-T patients with a significantly reduced naïve T-cell pool. Our study includes 69 A-T patients between 8 January 2002 and 1 December 2019. Nineteen cases of cancer were diagnosed in 17 patients (25%), with a median overall survival [OS; 95% cumulative indcidence (CI)] of 26·9 years for the entire cohort. The 15-year OS of 82·5% (72-95%) was significantly decreased among A-T patients with malignancies, who had a median OS of 2·11 years, with a two-year-estimated OS of 50·7% (31-82%). Haematological malignancies were the major causes of death within the initial years of life with a 15 times increased risk for death [HR (95% CI): 6·9 (3·1-15.2), P < 0·001] upon malignancy diagnosis. Male patients with A-T are at a higher cancer risk than their female counterparts. This manuscript highlights the need for cancer surveillance and prevention, as well as optimal treatment in this cohort.
24
A Single Ataxia Telangiectasia Gene with a Product Similar to PI-3 Kinase
Kinneret Savitsky, Anat Bar‐Shira, Shlomit Gilad et al. · Science · 1995 · 2.8K citations
Newborn Screening for Severe Combined Immunodeficiency in 11 Screening Programs in the United States
Antonia Kwan, Roshini S. Abraham, Robert J. Currier et al. · JAMA · 2014 · 673 citations
Medicine, Immunology, Pediatrics +17
Felipe Suárez, Nizar Mahlaoui, Danielle Canioni et al. · Journal of Clinical Oncology · 2014 · 251 citations · Full text
Medicine, Hematology, Oncology +17